Locally Advanced or Metastatic Pancreatic Adenocarcinoma

• Status: Enrolling by invitation
• Trial end date: 2026-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Multiple centers, uncontrolled, open-label, non-randomized single-arm study

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Health Research Institutes, Taiwan
• Collaborators: Chang Gung Memorial Hospital; China Medical University Hospital; Kaohsiung Medical University; National Cheng-Kung University Hospital; National Taiwan University Hospital
• Treatments: Gemcitabine; Leucovorin

Criteria

Inclusion Criteria:

1. Patients must have cyto-/histologically confirmed, recurrent or metastatic adenocarcinoma of the pancreas.

2. Patients have disease measurable or evaluable on x-ray, computed tomography scan, or physical examination.

3. Patients have no history of prior chemotherapy for metastatic pancreatic cancer. Patients who had received chemotherapy as in an adjuvant or neoadjuvant setting which was completed at least 6 months before recurrence are eligible.

4. Patients with prior radiotherapy are eligible if the irradiated area does not involve the only lesion of measurable / evaluable disease.

5. Baseline ECOG performance status is 2.

6. Patients have life expectancy of at least 12 weeks.

7. Patients have age 70 years.

8. Patients have adequate organ function.

9. Patients with biliary obstruction which is adequate drained before enrollment are eligible.

10. Patients agree to have an indwelling venous catheter implanted.

11. Women or men of reproductive potential should agree to use an effective contraceptive method.

12. All patients must be informed of the investigational nature of this study and must sign written informed consents.

Exclusion Criteria:

1. Patients who have major abdominal surgery, radiotherapy or other investigating agents within 4 weeks are not eligible. Patients who have palliative radiotherapy for bony metastasis will be eligible if the irradiated area does not involve the only lesion of measurable / evaluable disease.

2. Patients with metastatic lesion in central nervous system.

3. Patients with active infection.

4. Patients with active cardiopulmonary disease or history of ischemic heart disease.

5. Patients who have peripheral neuropathy > grade I of any etiology.

6. Patients who have serious concomitant systemic disorders incompatible with the study, i.e. poorly controlled diabetes mellitus, auto-immune disorders, cirrhosis of the liver, and the rest will be at the discretion of in-charged investigator.

7. Patients who have other prior or concurrent malignancy except for adequately treated in situ carcinoma of cervix or adequately.